The global critical care nutrition market was valued at $10,618.96 million in 2020, and is projected to reach $19,237.81 million by 2030, registering a CAGR of 6.1% from 2021 to 2030.
Critical care nutrition is referred to as the nutrition support therapy for critically ill patients to attain positive patient outcomes. In addition, critical care is known to be the provision of safe and optimal nutrition that needs to be provided to patients admitted to the ICU using evidence-based practice. This therapy is prescribed to patients suffering from chronic illness such as malnutrition, gastrointestinal disorder, and cancer. In addition, the nutrition therapy, if taken in early stages, may assist in decreasing the disease severity and reduce complications that are caused due to insufficiency of nutrition. Furthermore, decrease in length of stay in the ICU and decline in the rate of mortality in patient population who have undergone early nutritional therapy would help the market generate higher revenue in the forecast period.
Rise in prevalence of chronic disorders such as cancer and neurological disorders is the major factor that contributes toward the growth of the critical care nutrition market. According to the statistics given by the American Society of Clinical Oncology Journal in 2020, the incidence rate of cancer is higher among females, which is about 712,758 than in males, which is about 679,421 for the year 2020. The projected national cancer incidence burden in 2020 were 98.7 per 100,000 population that is approximately 1,392,179 patients as a conservative estimate. Furthermore, surge in the healthcare spending is anticipated to notably contribute toward the market growth.
According to the statistics given by the United Nations in 2020, about 727 million people are aged 65 years and above across the globe. This number is estimated to reach 1.5 billion by 2050. Thus, huge increase in the geriatric population, who are most susceptible to suffer from chronic diseases and require critical care nutrition for combatting with the condition is anticipated to fuel the market growth. However, lack of awareness regarding critical care nutrition for patients admitted in the ICU in underdeveloped countries will hinder the market growth.
In addition, the development of newer technologically advanced products and increased market potential in untapped emerging economies are expected to provide lucrative opportunities for the growth of the market.
The global critical care nutrition market is segmented into route of administration, application, age group and region. On the basis of route of administration, the market is categorized into enteral and parenteral. The applications covered in the study include cancer, neurological diseases, gastrointestinal disorders, and others. Depending on age group, the market is segregated into pediatric, adults, geriatric. The pediatric segment is further divided into enteral and parenteral nutrition. The adults segment is categorized into enteral and parenteral. The geriatric segment is further bifurcated into enteral and parenteral nutrition. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of route of administration, the enteral nutrition segment dominated in 2020, and is anticipated to continue this trend during the forecast period. However, parenteral nutrition segment is expected to help gain significant share in the next few years.
Critical care nutrition is referred to as the nutrition support therapy for critically ill patients to attain positive patient outcomes. In addition, critical care is known to be the provision of safe and optimal nutrition that needs to be provided to patients admitted to the ICU using evidence-based practice. This therapy is prescribed to patients suffering from chronic illness such as malnutrition, gastrointestinal disorder, and cancer. In addition, the nutrition therapy, if taken in early stages, may assist in decreasing the disease severity and reduce complications that are caused due to insufficiency of nutrition. Furthermore, decrease in length of stay in the ICU and decline in the rate of mortality in patient population who have undergone early nutritional therapy would help the market generate higher revenue in the forecast period.
Rise in prevalence of chronic disorders such as cancer and neurological disorders is the major factor that contributes toward the growth of the critical care nutrition market. According to the statistics given by the American Society of Clinical Oncology Journal in 2020, the incidence rate of cancer is higher among females, which is about 712,758 than in males, which is about 679,421 for the year 2020. The projected national cancer incidence burden in 2020 were 98.7 per 100,000 population that is approximately 1,392,179 patients as a conservative estimate. Furthermore, surge in the healthcare spending is anticipated to notably contribute toward the market growth.
According to the statistics given by the United Nations in 2020, about 727 million people are aged 65 years and above across the globe. This number is estimated to reach 1.5 billion by 2050. Thus, huge increase in the geriatric population, who are most susceptible to suffer from chronic diseases and require critical care nutrition for combatting with the condition is anticipated to fuel the market growth. However, lack of awareness regarding critical care nutrition for patients admitted in the ICU in underdeveloped countries will hinder the market growth.
In addition, the development of newer technologically advanced products and increased market potential in untapped emerging economies are expected to provide lucrative opportunities for the growth of the market.
The global critical care nutrition market is segmented into route of administration, application, age group and region. On the basis of route of administration, the market is categorized into enteral and parenteral. The applications covered in the study include cancer, neurological diseases, gastrointestinal disorders, and others. Depending on age group, the market is segregated into pediatric, adults, geriatric. The pediatric segment is further divided into enteral and parenteral nutrition. The adults segment is categorized into enteral and parenteral. The geriatric segment is further bifurcated into enteral and parenteral nutrition. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of route of administration, the enteral nutrition segment dominated in 2020, and is anticipated to continue this trend during the forecast period. However, parenteral nutrition segment is expected to help gain significant share in the next few years.
By application, the neurological diseases segment led the global market in 2020, and is anticipated to continue this trend in the near future. However, the cancer segment is expected to register the highest CAGR in the coming years.
Depending on patient group, the market is segregated into pediatric, adults, and geriatric. Presently, the pediatric segment accounts for majority of the share, owing to increase in number of patients suffering from chronic diseases such as diabetes, cancer, and gastrointestinal disorders. Furthermore, the geriatric segment is expected to grow at the highest CAGR in the coming years. This is attributed to increase in geriatric population that requires critical care nutrition.KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Route of Administration
- Enteral
- Parenteral
By Application
- Cancer
- Neurological Diseases
- Gastrointestinal Disorders
- Others
By End User
- Pediatric
- Enteral
- Parenteral
- Adults
- Enteral
- Parenteral
- Geriatric
- Enteral
- Parenteral
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Abbott
- Fresenius Kabi AG
- Danone
- Mead Johnson & Company, LLC,
- Baxter
- B.Braun Melsungen AG
- Nestle
- MEIJI HOLDINGS CO., LTD.
- RECKITT BENCKISER GROUP PLC.
- VICTUS, INC
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in healthcare spending for patient population
3.5.1.2. Increase in prevalence of ageing associated diseases
3.5.1.3. Rise in incidences of the targeted disease
3.5.1.4. Advantages offered by critical care nutrition
3.5.2. Restraints
3.5.2.1. Inadequate efficiency of nutritional care in critically ill patients
3.5.3. Opportunity
3.5.3.1. High market potential in emerging economies
3.5.4. Impact analysis
3.6. COVID-19 Impact Analysis on critical care nutrition Market
CHAPTER 4: CRITICAL CARE NUTRITION MARKET, BY ROUTE OF ADMINISTRATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Enteral
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Parenteral
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: CRITICAL CARE NUTRITION MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Neurological Diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.3.3. Gastrointestinal Disorders
5.3.4. Market size and forecast, by region
5.3.5. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: CRITICAL CARE NUTRITION MARKET, BY AGE GROUP
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.2.3. Market size and forecast, by route of administration
6.3. Adults
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.3.3. Market size and forecast, by route of administration
6.4. Geriatric
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
6.4.3. Market size and forecast, by route of administration
CHAPTER 7: CRITICAL CARE NUTRITION MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America market size and forecast, by Route of administration
7.2.3. North America market size and forecast, by Application
7.2.4. North America market size and forecast, by age group
7.2.5. Market size and forecast, by country
7.2.5.1. U. S.
7.2.5.1.1. Critical care nutrition market, for U. S., by Route of administration
7.2.5.1.2. Critical care nutrition market, for U. S., by Application
7.2.5.1.3. Critical care nutrition market, for U. S., by age group
7.2.5.2. Canada
7.2.5.2.1. Critical care nutrition market, for Canada, by Route of administration
7.2.5.2.2. Critical care nutrition market, for Canada, by Application
7.2.5.2.3. Critical care nutrition market, for Canada, by age group
7.2.5.3. Mexico
7.2.5.3.1. Critical care nutrition market, for Mexico, by Route of administration
7.2.5.3.2. Critical care nutrition market, for Mexico, by Application
7.2.5.3.3. Critical care nutrition market, for Mexico, by age group
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe market size and forecast, by Route of administration
7.3.3. Europe market size and forecast, by Application
7.3.4. Europe market size and forecast, by age group
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Critical care nutrition market, for Germany, by Route of administration
7.3.5.1.2. Critical care nutrition market, for Germany, by Application
7.3.5.1.3. Critical care nutrition market, for Germany, by age group
7.3.5.2. France
7.3.5.2.1. Critical care nutrition market, for France, by Route of administration
7.3.5.2.2. Critical care nutrition market, for France, by Application
7.3.5.2.3. Critical care nutrition market, for France, by age group
7.3.5.3. UK
7.3.5.3.1. Critical care nutrition market, for UK, by Route of administration
7.3.5.3.2. Critical care nutrition market, for UK, by Application
7.3.5.3.3. Critical care nutrition market, for UK, by age group
7.3.5.4. Italy
7.3.5.4.1. Critical care nutrition market, for Italy, by Route of administration
7.3.5.4.2. Critical care nutrition market, for Italy, by Application
7.3.5.4.3. Critical care nutrition market, for Italy, by age group
7.3.5.5. Spain
7.3.5.5.1. Critical care nutrition market, for Spain, by Route of administration
7.3.5.5.2. Critical care nutrition market, for Spain, by Application
7.3.5.5.3. Critical care nutrition market, for Spain, by age group
7.3.5.6. Rest of Europe
7.3.5.6.1. Critical care nutrition market, for Rest of Europe, by Route of administration
7.3.5.6.2. Critical care nutrition market, for Rest of Europe, by Application
7.3.5.6.3. Critical care nutrition market, for Rest of Europe, by age group
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific market size and forecast, by Route of administration
7.4.3. Asia-Pacific market size and forecast, by Application
7.4.4. Asia-Pacific market size and forecast, by age group
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Critical care nutrition market, for Japan, by Route of administration
7.4.5.1.2. Critical care nutrition market, for Japan, by Application
7.4.5.1.3. Critical care nutrition market, for Japan, by age group
7.4.5.2. China
7.4.5.2.1. Critical care nutrition market, for China, by Route of administration
7.4.5.2.2. Critical care nutrition market, for China, by Application
7.4.5.2.3. Critical care nutrition market, for China, by age group
7.4.5.3. Australia
7.4.5.3.1. Critical care nutrition market, for Australia, by Route of administration
7.4.5.3.2. Critical care nutrition market, for Australia, by Application
7.4.5.3.3. Critical care nutrition market, for Australia, by age group
7.4.5.4. India
7.4.5.4.1. Critical care nutrition market, for India, by Route of administration
7.4.5.4.2. Critical care nutrition market, for India, by Application
7.4.5.4.3. Critical care nutrition market, for India, by age group
7.4.5.5. South Korea
7.4.5.5.1. Critical care nutrition market, for South Korea, by Route of administration
7.4.5.5.2. Critical care nutrition market, for South Korea, by Application
7.4.5.5.3. Critical care nutrition market, for South Korea, by age group
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Critical care nutrition market, for Rest of Asia-Pacific, by Route of administration
7.4.5.6.2. Critical care nutrition market, for Rest of Asia-Pacific, by Application
7.4.5.6.3. Critical care nutrition market, for Rest of Asia-Pacific, by age group
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by Route of administration
7.5.3. LAMEA market size and forecast, by Application
7.5.4. LAMEA market size and forecast, by age group
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Critical care nutrition market, for Brazil, by Route of administration
7.5.5.1.2. Critical care nutrition market, for Brazil, by Application
7.5.5.1.3. Critical care nutrition market, for Brazil, by age group
7.5.5.2. Saudi Arabia
7.5.5.2.1. Critical care nutrition market, for Saudi Arabia, by Route of administration
7.5.5.2.2. Critical care nutrition market, for Saudi Arabia, by Application
7.5.5.2.3. Critical care nutrition market, for Saudi Arabia, by age group
7.5.5.3. South Africa
7.5.5.3.1. Critical care nutrition market, for South Africa, by Route of administration
7.5.5.3.2. Critical care nutrition market, for South Africa, by Application
7.5.5.3.3. Critical care nutrition market, for South Africa, by age group
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Critical care nutrition market, for Rest of LAMEA, by Route of administration
7.5.5.4.2. Critical care nutrition market, for Rest of LAMEA, by Application
7.5.5.4.3. Critical care nutrition market, for Rest of LAMEA, by age group
CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company Snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. BAXTER INTERNATIONAL, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. B. BRAUN MELSUNGEN AG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. DANONE S. A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. FRESENIUS KABI AKTIENGESELLSCHAFT
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. HORMEL FOODS CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MEIJI HOLDINGS CO., LTD.
8.7.1. Company overview
8.7.2. Operating business segments
8.7.3. Product portfolio
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. NESTLE S. A.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. RECKITT BENCKISER GROUP PLC
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. VICTUS INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.6. Key strategic moves and developmentsLIST OF TABLES
TABLE 01. CRITICAL CARE NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 02. CRITICAL CARE NUTRITION MARKET, FOR ENTERAL, BY REGION, 2020-2030 ($MILLION)
TABLE 03. CRITICAL CARE NUTRITION MARKET, FOR PARENTERAL, BY REGION, 2020-2030 ($MILLION)
TABLE 04. CRITICAL CARE NUTRITION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 05. CRITICAL CARE NUTRITION MARKET, FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 06. CRITICAL CARE NUTRITION MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 07. CRITICAL CARE NUTRITION MARKET, FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 08. CRITICAL CARE NUTRITION MARKET, FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 09. CRITICAL CARE NUTRITION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 10. CRITICAL CARE NUTRITION MARKET FOR PEDIATRIC, BY REGION, 2020-2030 ($MILLION)
TABLE 11. CRITICAL CARE NUTRITION MARKET FOR PEDIATRIC, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 12. CRITICAL CARE NUTRITION MARKET FOR ADULTS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. CRITICAL CARE NUTRITION MARKET FOR ADULTS, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 14. CRITICAL CARE NUTRITION MARKET FOR GERIATRIC, BY REGION, 2020-2030 ($MILLION)
TABLE 15. CRITICAL CARE NUTRITION MARKET FOR GERIATRIC, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 16. CRITICAL CARE NUTRITION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17. CRITICAL CARE NUTRITION MARKET, FOR NORTH AMERICA, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 18. CRITICAL CARE NUTRITION MARKET, FOR NORTH AMERICA, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 19. CRITICAL CARE NUTRITION MARKET, FOR NORTH AMERICA, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 20. CRITICAL CARE NUTRITION MARKET, FOR NORTH AMERICA, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21. CRITICAL CARE NUTRITION MARKET, FOR U.S., BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 22. CRITICAL CARE NUTRITION MARKET, FOR U.S., BY APPLICATION, 2020-2030
TABLE 23. CRITICAL CARE NUTRITION MARKET, FOR U.S., BY AGE GROUP, 2020-2030
TABLE 24. CRITICAL CARE NUTRITION MARKET, FOR CANADA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 25. CRITICAL CARE NUTRITION MARKET, FOR CANADA, BY APPLICATION, 2020-2030
TABLE 26. CRITICAL CARE NUTRITION MARKET, FOR CANADA, BY AGE GROUP, 2020-2030
TABLE 27. CRITICAL CARE NUTRITION MARKET, FOR MEXICO, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 28. CRITICAL CARE NUTRITION MARKET, FOR MEXICO, BY APPLICATION, 2020-2030
TABLE 29. CRITICAL CARE NUTRITION MARKET, FOR MEXICO, BY AGE GROUP, 2020-2030
TABLE 30. CRITICAL CARE NUTRITION MARKET, FOR EUROPE, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 31. CRITICAL CARE NUTRITION MARKET, FOR EUROPE, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 32. CRITICAL CARE NUTRITION MARKET, FOR EUROPE, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 33. CRITICAL CARE NUTRITION MARKET, FOR EUROPE CRITICAL CARE NUTRITION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34. CRITICAL CARE NUTRITION MARKET, FOR GERMANY, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 35. CRITICAL CARE NUTRITION MARKET, FOR GERMANY, BY APPLICATION, 2020-2030
TABLE 36. CRITICAL CARE NUTRITION MARKET, FOR GERMANY, BY AGE GROUP, 2020-2030
TABLE 37. CRITICAL CARE NUTRITION MARKET, FOR FRANCE, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 38. CRITICAL CARE NUTRITION MARKET, FOR FRANCE, BY APPLICATION, 2020-2030
TABLE 39. CRITICAL CARE NUTRITION MARKET, FOR FRANCE, BY AGE GROUP, 2020-2030
TABLE 40. CRITICAL CARE NUTRITION MARKET, FOR UK, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 41. CRITICAL CARE NUTRITION MARKET, FOR UK, BY APPLICATION, 2020-2030
TABLE 42. CRITICAL CARE NUTRITION MARKET, FOR UK, BY AGE GROUP, 2020-2030
TABLE 43. CRITICAL CARE NUTRITION MARKET, FOR ITALY, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 44. CRITICAL CARE NUTRITION MARKET, FOR ITALY, BY APPLICATION, 2020-2030
TABLE 45. CRITICAL CARE NUTRITION MARKET, FOR ITALY, BY AGE GROUP, 2020-2030
TABLE 46. CRITICAL CARE NUTRITION MARKET, FOR SPAIN, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 47. CRITICAL CARE NUTRITION MARKET, FOR SPAIN, BY APPLICATION, 2020-2030
TABLE 48. CRITICAL CARE NUTRITION MARKET, FOR SPAIN, BY AGE GROUP, 2020-2030
TABLE 49. CRITICAL CARE NUTRITION MARKET, FOR REST OF EUROPE, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 50. CRITICAL CARE NUTRITION MARKET, FOR REST OF EUROPE, BY APPLICATION, 2020-2030
TABLE 51. CRITICAL CARE NUTRITION MARKET, FOR REST OF EUROPE, BY AGE GROUP, 2020-2030
TABLE 52. CRITICAL CARE NUTRITION MARKET, FOR ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 53. CRITICAL CARE NUTRITION MARKET, FOR ASIA-PACIFIC, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 54. CRITICAL CARE NUTRITION MARKET, FOR ASIA-PACIFIC, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 55. CRITICAL CARE NUTRITION MARKET, FOR ASIA-PACIFIC , BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56. CRITICAL CARE NUTRITION MARKET, FOR JAPAN, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 57. CRITICAL CARE NUTRITION MARKET, FOR JAPAN, BY APPLICATION, 2020-2030
TABLE 58. CRITICAL CARE NUTRITION MARKET, FOR JAPAN, BY AGE GROUP, 2020-2030
TABLE 59. CRITICAL CARE NUTRITION MARKET, FOR CHINA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 60. CRITICAL CARE NUTRITION MARKET, FOR CHINA, BY APPLICATION, 2020-2030
TABLE 61. CRITICAL CARE NUTRITION MARKET, FOR CHINA, BY AGE GROUP, 2020-2030
TABLE 62. CRITICAL CARE NUTRITION MARKET, FOR AUSTRALIA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 63. CRITICAL CARE NUTRITION MARKET, FOR AUSTRALIA, BY APPLICATION, 2020-2030
TABLE 64. CRITICAL CARE NUTRITION MARKET, FOR AUSTRALIA, BY AGE GROUP, 2020-2030
TABLE 65. CRITICAL CARE NUTRITION MARKET, FOR INDIA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 66. CRITICAL CARE NUTRITION MARKET, FOR INDIA, BY APPLICATION, 2020-2030
TABLE 67. CRITICAL CARE NUTRITION MARKET, FOR INDIA, BY AGE GROUP, 2020-2030
TABLE 68. CRITICAL CARE NUTRITION MARKET, FOR SOUTH KOREA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 69. CRITICAL CARE NUTRITION MARKET, FOR SOUTH KOREA, BY APPLICATION, 2020-2030
TABLE 70. CRITICAL CARE NUTRITION MARKET, FOR SOUTH KOREA, BY AGE GROUP, 2020-2030
TABLE 71. CRITICAL CARE NUTRITION MARKET, FOR REST OF ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 72. CRITICAL CARE NUTRITION MARKET, FOR REST OF ASIA-PACIFIC, BY APPLICATION, 2020-2030
TABLE 73. CRITICAL CARE NUTRITION MARKET, FOR REST OF ASIA-PACIFIC, BY AGE GROUP, 2020-2030
TABLE 74. CRITICAL CARE NUTRITION MARKET, FOR LAMEA, BY ROUTE OF ADMINISTRATION, 2020-2030, ($MILLION)
TABLE 75. CRITICAL CARE NUTRITION MARKET, FOR LAMEA, BY APPLICATION, 2020-2030, ($MILLION)
TABLE 76. CRITICAL CARE NUTRITION MARKET, FOR LAMEA, BY AGE GROUP, 2020-2030, ($MILLION)
TABLE 77. CRITICAL CARE NUTRITION MARKET, FOR LAMEA, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78. CRITICAL CARE NUTRITION MARKET, FOR BRAZIL, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 79. CRITICAL CARE NUTRITION MARKET, FOR BRAZIL, BY APPLICATION, 2020-2030
TABLE 80. CRITICAL CARE NUTRITION MARKET, FOR BRAZIL, BY AGE GROUP, 2020-2030
TABLE 81. CRITICAL CARE NUTRITION MARKET, FOR SAUDI ARABIA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 82. CRITICAL CARE NUTRITION MARKET, FOR SAUDI ARABIA, BY APPLICATION, 2020-2030
TABLE 83. CRITICAL CARE NUTRITION MARKET, FOR SAUDI ARABIA, BY AGE GROUP, 2020-2030
TABLE 84. CRITICAL CARE NUTRITION MARKET, FOR SOUTH AFRICA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 85. CRITICAL CARE NUTRITION MARKET, FOR SOUTH AFRICA, BY APPLICATION, 2020-2030
TABLE 86. CRITICAL CARE NUTRITION MARKET, FOR SOUTH AFRICA, BY AGE GROUP, 2020-2030
TABLE 87. CRITICAL CARE NUTRITION MARKET, FOR REST OF LAMEA, BY ROUTE OF ADMINISTRATION, 2020-2030
TABLE 88. CRITICAL CARE NUTRITION MARKET, FOR REST OF LAMEA, BY APPLICATION, 2020-2030
TABLE 89. CRITICAL CARE NUTRITION MARKET, FOR REST OF LAMEA, BY AGE GROUP, 2020-2030
TABLE 90. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 91. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 92. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 93. BAXTER: COMPANY SNAPSHOT
TABLE 94. BAXTER: OPERATING SEGMENTS
TABLE 95. BAXTER: PRODUCT PORTFOLIO
TABLE 96. B. BRAUN: COMPANY SNAPSHOT
TABLE 97. B. BRAUN: OPERATING SEGMENTS
TABLE 98. B. BRAUN: PRODUCT PORTFOLIO
TABLE 99. DANONE: COMPANY SNAPSHOT
TABLE 100. DANONE: OPERATING SEGMENTS
TABLE 101. DANONE: PRODUCT PORTFOLIO
TABLE 102. FRESENIUS KABI AG: COMPANY SNAPSHOT
TABLE 103. FRESENIUS KABI AG: OPERATING SEGMENTS
TABLE 104. FRESENIUS KABI AG: PRODUCT PORTFOLIO
TABLE 105. HORMEL FOODS : COMPANY SNAPSHOT
TABLE 106. HORMEL FOODS : OPERATING SEGMENTS
TABLE 107. HORMEL FOODS : PRODUCT PORTFOLIO
TABLE 108. MEIJI HOLDINGS: COMPANY SNAPSHOT
TABLE 109. MEIJI HOLDINGS: OPERATING SEGMENTS
TABLE 110. MEIJI HOLDINGS: PRODUCT PORTFOLIO
TABLE 111. NESTLE : COMPANY SNAPSHOT
TABLE 112. NESTLE : OPERATING SEGMENTS
TABLE 113. NESTLE: PRODUCT PORTFOLIO
TABLE 114. RECKITT: COMPANY SNAPSHOT
TABLE 115. RECKITT: OPERATING SEGMENTS
TABLE 116. RECKITT: PRODUCT PORTFOLIO
TABLE 117. VICTUS: COMPANY SNAPSHOT
TABLE 118. VICTUS: OPERATING SEGMENTS
TABLE 119. VICTUS: PRODUCT PORTFOLIOLIST OF FIGURES
FIGURE 01. CRITICAL CARE NUTRITION MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. LOW BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR ENTERAL, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR PARENTERAL, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR CANCER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, FOR PEDIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, ADULTS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF CRITICAL CARE NUTRITION MARKET, GERIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. ABBOTT LABORATORIES: REVENUE, 2018-2020 ($MILLION)
FIGURE 23. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 25. BAXTER: REVENUE, 2018-2020 ($MILLION)
FIGURE 26. BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 28. B. BRAUN: REVENUE, 2020 (%)
FIGURE 29. B. BRAUN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30. DANONE: REVENUE, 2018-2020 ($MILLION)
FIGURE 31. DANONE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. DANONE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33. FRESENIUS KABI AG: REVENUE, 2018-2020 ($MILLION)
FIGURE 34. FRESENIUS KABI AG: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. FRESENIUS KABI AG: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 36. HORMEL FOODS: REVENUE, 2018-2020 ($MILLION)
FIGURE 37. HORMEL FOODS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38. HORMEL FOODS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39. MEIJI HOLDINGS: REVENUE, 2018-2020 ($MILLION)
FIGURE 40. MEIJI HOLDINGS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41. NESTLE: REVENUE, 2018-2020 ($MILLION)
FIGURE 42. NESTLE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. NESTLE: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 44. RECKITT: REVENUE, 2018-2020 ($MILLION)
FIGURE 45. RECKITT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46. RECKITT: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
Companies Mentioned
- Abbott Laboratories
- Fresenius Kabi AG
- Danone S.A.
- Mead Johnson & Company LLC
- Baxter International Inc.
- B.Braun Melsungen AG
- Nestle S.A.
- Meiji Holdings Co., Ltd.
- Reckitt Benckiser Group PLC.
- Victus, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 229 |
| Published | July 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 10618.96 million |
| Forecasted Market Value ( USD | $ 19237.81 million |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
